Benzinga · Feb 20, 2026
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
DW
NASDAQ · DWTX
Dogwood Therapeutics, Inc.
Healthcare · Biotechnology
$1.98
Down-$0.02 (-1.26%)
Updated Aug 14, 2026, 4:56 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.96M
- P/E ratio
- -0.31
- Dividend yield
- 0.00%
- 52-week range
- $1.28 – $3.50
- Volume
- 22.3K
- Avg. volume
- 758.26K
Price performance
DWTX price history
1M range · 21 trading sessions · Daily adjusted prices
DWTX closed at $1.98 after 21 trading sessions, up 44.53% for the selected period.
- Last close
- $1.98
- Period change
- +44.53%
- Period low
- $1.37
- Period high
- $1.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $1.92 | $2.005 | $1.89 | $1.98 | 22.3K |
| Aug 12, 2026 | $1.85 | $2.075 | $1.845 | $1.925 | 58.37K |
| Aug 11, 2026 | $1.83 | $1.85 | $1.75 | $1.84 | 52.54K |
| Aug 10, 2026 | $1.8101 | $1.85 | $1.73 | $1.83 | 26.44K |
| Aug 7, 2026 | $1.765 | $1.805 | $1.765 | $1.805 | 6.75K |
| Aug 6, 2026 | $1.80 | $1.835 | $1.6501 | $1.75 | 65.86K |
| Aug 5, 2026 | $1.78 | $1.85 | $1.73 | $1.83 | 14.67K |
| Aug 4, 2026 | $1.7112 | $1.89 | $1.7112 | $1.79 | 72.51K |
| Aug 3, 2026 | $1.65 | $1.74 | $1.55 | $1.71 | 84.35K |
| Jul 31, 2026 | $1.54 | $1.64 | $1.50 | $1.64 | 50.18K |
| Jul 30, 2026 | $1.52 | $1.62 | $1.47 | $1.58 | 8.4K |
| Jul 29, 2026 | $1.59 | $1.59 | $1.46 | $1.54 | 67.11K |
| Jul 28, 2026 | $1.53 | $1.57 | $1.49 | $1.55 | 36.57K |
| Jul 27, 2026 | $1.52 | $1.54 | $1.48 | $1.53 | 4.55K |
| Jul 24, 2026 | $1.54 | $1.57 | $1.48 | $1.50 | 18.88K |
| Jul 23, 2026 | $1.46 | $1.57 | $1.45 | $1.54 | 40.68K |
| Jul 22, 2026 | $1.39 | $1.70 | $1.35 | $1.46 | 170.87K |
| Jul 21, 2026 | $1.37 | $1.44 | $1.36 | $1.40 | 8.82K |
| Jul 20, 2026 | $1.3698 | $1.405 | $1.335 | $1.38 | 32.5K |
| Jul 17, 2026 | $1.36 | $1.4272 | $1.342 | $1.38 | 73.87K |
| Jul 16, 2026 | $1.44 | $1.44 | $1.37 | $1.37 | 70.9K |
Latest DWTX news
The latest Smart Investors Daily articles mentioning DWTX.
Stock researchCompany · Overview
DWTX research
Overview
Company profile and research snapshot.
Company profile
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 2, 2026
DWTX: Financing Secures Funding Through Phase 2b Data Readout
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Financial Update On January 15, 2026, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement. An aggregate of 4,386,037
Yahoo · Feb 2, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial.
Benzinga · Feb 2, 2026
Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated -
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
